The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Nutrition and ExerciseNutrition and Exercise
Rollover images to visit our other forums!
  • Email Email
  • Glossary Glossary

formerly tnx-355 halt?
Feb 25, 2013

Nelson, I received word that TaiMed was stoping production of this drug in phase 2 trials? Is there any truth to this? I am on this (IV) drug for over a year and FINALLY viral suppressed after 20 years! To say the least I will be grateful for info. re: this....Many thanks....Texas here!

Response from Mr. Vergel

That is not true. All patients receiving ibalizumab (a research entry inhibitor that used to be called TNX-355) through the extension of Taimed's phase 2 study will keep receiving the intraveneously administered drug every two weeks or one month for as long as we need it. Like you, this drug has also helped my HIV viral load remain undetectable for the first time in 27 years.

The company is testing a new subcutaneous injection formulation to replace the IV formulation. But this process will take at least a year or more. I am hopeful that the results will be good so that we can switch to a self administered dosing that will not require for us to go to the doctor every two weeks.


why wont the feds fund this for us

  • Email Email
  • Glossary Glossary



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint